Alexion Pharmaceuticals announces 40 new jobs for Athlone

By Business & Finance
03 February 2014

Alexion Pharma Ireland Trading, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that it has agreed to purchase a vialling facility in Athlone. The closing of the acquisition is expected to occur during the first quarter of 2014.

In July last year, Alexion announced plans to expand its global presence with the opening of a new office and laboratory facility in Dublin in conjunction with the company’s decision to establish a global supply chain facility in Ireland.  The acquisition of the facility in Athlone is part of the plan to establish global supply chain operations in Ireland.

Stephen Squinto, PhD, executive vice president and chief global operations officer at Alexion stated: “The acquisition of the Athlone facility is a sign of our commitment to growing our newly established global supply chain operation in Ireland. As we continue to grow and expand our operations to serve more patients, this facility will help us to provide life-transforming medicines to patients in Europe and around the world.”

Barry O’Leary, CEO of IDA Ireland added: “Alexion is a highly innovative biopharmaceutical company and its decision to expand its activities in Ireland is very welcome. The facility in Athlone strengthens the life sciences cluster in the Midlands region. IDA Ireland continues to attract the leading players in the BioPharma industry with seven of the top ten global BioPharma companies having strategic operations here.”

Alexion currently employs people at its Park West facility and is expanding its workforce in Ireland. Following the appropriate validation processes and regulatory approval, the Athlone facility will become Alexion’s first company-owned vialling facility.

Recognised by Forbes Magazine as the second most innovative company in the world two years in a row, Alexion is a global biopharmaceutical company focused on the development and delivery of therapies for severe and life-threatening rare disorders. Today, Alexion has more than 1,800 employees and operations in place to serve patients in nearly 50 countries around the world